Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, ...

Dyadic international was awarded a $3 million grant from the Bill & Melinda Gates Foundation to fund the development of ...

总之，Dyadic International 2024年第三季度业绩电话会议揭示了公司财务状况强劲，在产品开发和商业化方面取得重大进展。公司的战略合作伙伴关系以及对生物技术板块高增长领域的关注，使其为持续成功奠定了良好基础。 Dyadic ...

周四，H.C. Wainwright重申了对Dyadic International (NASDAQ:DYAI)的买入评级和6.00美元的目标价，此前该公司宣布2024年第三季度收入大幅增长。这家生物技术公司报告季度收入显著增加，2024年第三季度收入为1,958,000美元，而去年同期为397,000美元。

Dyadic International, Inc. (NASDAQ:DYAI) Q3 2024 Earnings Call Transcript November 16, 2024 Operator: Operator: Good evening, ...

Revenue: Revenue for the three months ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 ...

Analysts at HC Wainwright issued their FY2024 earnings estimates for Dyadic International in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst V. Bernardino ...

Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical ...

Good evening, and welcome to Dyadic International Q3 2024 Conference Call. Currently, all participants are in a listen-only mode. Following management’s prepared remarks, there will be a brief ...

Dyadic International Inc. ( (DYAI) ) has released its Q3 earnings. Here is a breakdown of the information Dyadic International Inc. presented ...

The latest announcement is out from Dyadic International ( (DYAI) ).

Dyadic国际(DYAI)发布Q3财报，2024财年前三财季累计收入267.80万美元，去年同期累计收入为221.23万美元，同比增长21.05%。 2024财年前三财季累计净亏损425.83万美元，去年同期累计净亏损为472.37万美元，同比缩小9.85%。 本财年累计基本每股收益为-0.15美元，去年同期为-0.16美元。 公司所属行业为生物科技。 Dyadic International, ...